Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross PI3K Inhibitor Prior Auth | Open…
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.592

    Phosphoinositide 3-kinase (PI3K) Inhibitors

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.592 alerts

    Get alerted when Policy 5.01.592 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization for specified oral phosphoinositide 3-kinase (PI3K) pathway inhibitors used to treat selected cancers, activated PI3K delta syndrome, and PIK3CA-related overgrowth spectrum. The requirements apply to providers submitting coverage requests for these medications.

    Policy Summary
    PayerPremera Bluecross
    PolicyPhosphoinositide 3-kinase (PI3K) Inhibitors
    Policy CodePolicy 5.01.592
    Change TypeModified
    Effective DateSep 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit medical records documenting that medical-necessity criteria are met, including office visit notes with the diagnosis, relevant history, physical evaluation, and medication history.
    SourceLink
    POLICY UPDATE CHANGES

    Added Truqap (capivasertib) coverage criteria for adults with metastatic androgen pathway modulation-naive or sensitive prostate cancer that is PTEN-deficient.

    Removed Aliqopa (copanlisib) coverage criteria because the medication was discontinued.

    Updated the initial authorization period for all other reviews of listed oral drugs from 3 months to 6 months.

    Updated Piqray (alpelisib) breast cancer criteria to limit the dose to 300 mg once daily.

    Removed the ECOG performance status requirement of 0 or 1 from Itovebi (inavolisib) criteria.

    6 monthsMaximum initial authorization period
    12 monthsMaximum reauthorization period
    6

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Oral drugs managed through the pharmacy benefit
    300 mg once dailyUpdated Piqray breast cancer dose limit
    1New Truqap prostate cancer indication
    1Drug removed from coverage criteria

    Drug-Specific Coverage Criteria

    Copiktra (duvelisib)

    Copiktra is medically necessary when all of the following criteria are met:

    Copiktra eligibility: The individual has relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), is aged 18 years or older, and has had at least two prior systemic therapies.Age >=18 years; >=2 prior systemic therapies

    Itovebi (inavolisib) for breast cancer

    Itovebi is medically necessary for the specified breast cancer indication when all of the following criteria are met:

    Itovebi breast cancer eligibility: The individual is an adult with endocrine-resistant PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer; has experienced disease progression following at least one line of endocrine therapy in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy; receives Itovebi in combination with Ibrance (palbociclib) and fulvestrant as first-line metastatic therapy; has not experienced disease progression on or following another PI3K inhibitor; Itovebi is prescribed by or in consultation with an oncologist; and the dose is limited to 9 mg once daily.Age >=18 years; dose <=9 mg once daily

    Joenja (leniolisib)

    Joenja is medically necessary for activated phosphoinositide 3-kinase delta syndrome (APDS) when all of the following criteria are met:

    Joenja eligibility: The individual is aged 12 years or older, is diagnosed with APDS, has a documented APDS-associated PI3K delta gene mutation with a documented variant in either PIK3CD or PIK3R1, Joenja is prescribed by or in consultation with an oncologist, medical geneticist, or hematologist, and the dose is limited to 140 mg per day taken as 70 mg twice daily.Age >=12 years; dose <=140 mg/day

    Piqray (alpelisib) for breast cancer

    Piqray is medically necessary for HR-positive, HER2-negative breast cancer when all of the following criteria are met:

    Piqray breast cancer eligibility: The individual is aged 18 years or older; has HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer detected by an FDA-approved test; has experienced progression on or after an endocrine-based regimen; Piqray is used in combination with fulvestrant; and the dose is limited to 300 mg once daily.Age >=18 years; dose <=300 mg once daily

    Piqray (alpelisib) for PROS

    Piqray is medically necessary for PIK3CA-related overgrowth spectrum (PROS) when all of the following criteria are met:

    Piqray PROS eligibility: The individual is aged 18 years or older, is diagnosed with PROS, has at least one target lesion identified on imaging, has a documented PIK3CA gene mutation, Piqray is prescribed by or in consultation with an oncologist, geneticist, or hematologist, and the dose is limited to 250 mg once daily.Age >=18 years; dose <=250 mg once daily

    Truqap (capivasertib) for prostate cancer

    Truqap is medically necessary for metastatic prostate cancer when all of the following criteria are met:

    Truqap prostate cancer eligibility: The individual is aged 18 years or older; has metastatic androgen pathway modulation-naive or sensitive prostate cancer; is PTEN-deficient; Truqap is used in combination with abiraterone, prednisone, and androgen deprivation therapy documented by concurrent use of a gonadotropin-releasing hormone (GnRH) analog or prior bilateral orchiectomy; and the dose is limited to 400 mg twice daily for 4 days followed by 3 days off.Age >=18 years; dose <=400 mg twice daily for 4 days followed by 3 days off

    Vijoice (alpelisib)

    Vijoice is medically necessary for PROS when all of the following criteria are met:

    Vijoice eligibility: The individual is aged 2 years or older, is diagnosed with PROS, has at least one target lesion identified on imaging, and Vijoice is prescribed by or in consultation with an oncologist, geneticist, or hematologist.Age >=2 years

    Zydelig (idelalisib)

    Zydelig is medically necessary for relapsed CLL when all of the following criteria are met:

    Zydelig eligibility: The individual has relapsed chronic lymphocytic leukemia (CLL); Zydelig is used in combination with rituximab for an individual for whom rituximab alone would be considered appropriate therapy because of other comorbidities; and the dose is limited to 300 mg per day taken as 150 mg twice daily.Dose <=300 mg/day

    Zydelig is not indicated and is not recommended for first-line treatment of any individual.

    All uses of drugs in this policy for conditions not outlined in the policy are considered investigational and are not eligible under the stated medical-necessity criteria.

    Zydelig (idelalisib) is not indicated or recommended for first-line treatment of any individual.

    Coverage criteria for Aliqopa (copanlisib) were removed because the medication was discontinued.

    Historical HCPCS Codes

    Historical HCPCS CodesHCPCS
    J9057HCPCS code for Aliqopa (copanlisib); removed from the policy in the September 2026 update
    J9999HCPCS code removed in the January 2019 coding update

    Authorization and Documentation Requirements

    Prior Authorization

    Drug-Specific Prior Authorization

    Obtain authorization for the specific PI3K inhibitor and indication by applying the drug-specific medical-necessity criteria and the product's current U.S. Food and Drug Administration (FDA) dosage and administration prescribing information.

    • Coverage is evaluated against the criteria applicable to the requested drug and indication.
    • Dose and administration must remain consistent with FDA-approved labeling.
    Prior Authorization

    Authorization Duration

    Initial authorization for drugs in this policy may be approved for up to 6 months. Reauthorization may be approved for up to 12 months when the drug-specific coverage criteria remain met and continued positive clinical response is documented.

    • For Piqray breast cancer, Truqap, Copiktra, Itovebi, Joenja, and Zydelig reviews, submit documentation of ongoing response for reauthorization.
    • For Piqray PROS and Vijoice, reauthorization may be approved for up to 12 months when criteria remain met and chart notes document a reduction in the sum of measurable target-lesion volume from baseline.

    PI3K Inhibitor Overview

    PI3K inhibitors block one or more enzymes in an intracellular signaling pathway involved in cell growth. This policy addresses these agents for selected hematologic malignancies, breast cancer, prostate cancer, activated PI3K delta syndrome, and PIK3CA-related overgrowth spectrum. Oral agents listed in the policy are managed through the pharmacy benefit.

    Clinical Definitions

    HER2-negative
    Testing methodHER2 status is assessed by immunohistochemical testing or in situ hybridization.
    HER2-negative resultImmunohistochemical intensity of 0 or 1+ is HER2-negative.
    Confirmatory resultAn immunohistochemical intensity of 2+ is HER2-negative when there is no amplification on in situ hybridization.
    Activated phosphoinositide 3-kinase delta syndrome (APDS)
    ConditionActivated phosphoinositide 3-kinase delta syndrome (APDS).
    Required mutationA documented APDS-associated PI3K delta gene mutation is required.
    Acceptable gene variants

    Initial Authorization

    Initial authorization

    Initial authorization may be approved for up to 6 months when all of the following criteria are met:

    Initial authorization: The applicable drug-specific medical-necessity criteria are met, and use follows the product's U.S. Food and Drug Administration dosage and administration prescribing information.Up to 6 months

    Reauthorization Requirements

    General continuation therapy

    Reauthorization may be approved for up to 12 months when all of the following criteria are met:

    General continuation: The applicable drug-specific coverage criteria continue to be met, and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.Up to 12 months

    Piqray for PROS and Vijoice continuation

    Reauthorization for Piqray used for PROS and Vijoice may be approved for up to 12 months when all of the following criteria are met:

    PROS continuation: The applicable drug-specific coverage criteria continue to be met, chart notes demonstrate a positive clinical response to therapy, and the sum of measurable target lesion volume is reduced from baseline.Up to 12 months; reduction in measurable target lesion volume from baseline

    Prerequisite Therapy

    StepRequirementException
    1For Truqap (capivasertib) for HR-positive, HER2-negative locally advanced or metastatic breast cancer, the individual must have tried Piqray (alpelisib) and experienced intolerance without disease progression.The Piqray trial is not required when the individual has a specific solitary AKT1 or PTEN mutation that is not sensitive to Piqray.

    Drug-Specific Dose Limits

    Itovebi (inavolisib)
    DrugItovebi (inavolisib).
    Dose9 mg once daily.
    Applicable useThe policy specifies this limit for eligible endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer.
    Joenja (leniolisib)
    DrugJoenja (leniolisib).
    Total daily dose140 mg per day.
    AdministrationTaken as 70 mg twice daily.
    Policy Summary
    PayerPremera Bluecross
    PolicyPhosphoinositide 3-kinase (PI3K) Inhibitors
    Policy CodePolicy 5.01.592
    Change TypeModified
    Effective DateSep 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit medical records documenting that medical-necessity criteria are met, including office visit notes with the diagnosis, relevant history, physical evaluation, and medication history.
    SourceLink
    On This Page
    Drug-Specific Coverage CriteriaHistorical HCPCS CodesAuthorization and Documentation RequirementsPI3K Inhibitor OverviewClinical DefinitionsInitial AuthorizationReauthorization RequirementsPrerequisite TherapyDrug-Specific Dose Limits
    Billing Rule

    Initial Authorization for Other Oral Drugs

    For other listed oral-drug reviews, the updated initial authorization period is up to 6 months. Apply the policy's program administration and authorization rules when submitting the review.

    • The initial duration for these reviews was updated from 3 months to 6 months.
    • Confirm that the requested drug, indication, dose, and documentation satisfy the applicable policy criteria.
    Step Therapy

    Truqap Breast Cancer Step Therapy or Exception

    For Truqap breast cancer treatment, document the required relationship to Piqray and the qualifying molecular exception before requesting authorization.

    • Truqap must be used in combination with fulvestrant and the individual must not have experienced disease progression on or following another PI3K/AKT/PTEN inhibitor.
    • The individual must have either tried Piqray and had intolerance without disease progression, or have a solitary AKT1 or PTEN mutation that is not sensitive to Piqray.
    • The prescribed dose must be limited to 400 mg twice daily for 4 days, followed by 3 days off.
    Documentation Required

    Medical Records Required

    Submit medical records supporting medical necessity for the requested drug and indication. The records must establish that the applicable coverage criteria are met.

    • Include office visit notes with the diagnosis, relevant history, physical evaluation, and medication history.
    • Include documentation of the requested indication, prior therapies, relevant testing or mutation results, prescribed dose, and other drug-specific criteria when applicable.
    Documentation Required

    Document Ongoing Clinical Response

    For reauthorization, submit current chart notes showing that the individual continues to have a positive clinical response to therapy.

    • For Piqray PROS and Vijoice, document a reduction in the sum of measurable target-lesion volume from baseline.
    • Ensure the submitted records also show that the drug-specific coverage criteria remain met.
    Denial Risk

    Unlisted Indications

    Uses of drugs in this policy for conditions not outlined in the policy are considered investigational and are not eligible under the stated coverage criteria.

    • Review the requested indication against the policy before submitting authorization.
    • The medication must also be used consistently with its FDA dosage and administration prescribing information.
    Denial Risk

    Zydelig First-Line Use

    Zydelig is not indicated and is not recommended for first-line treatment of any individual.

    • Do not request first-line Zydelig treatment under this policy.
    • The covered Zydelig CLL use is relapsed CLL in combination with rituximab when rituximab alone would otherwise be appropriate because of comorbidities, subject to the stated dose limit.
    Denial Risk

    Insufficient Continuation Response

    Reauthorization requires the applicable drug-specific criteria to remain met and current documentation of a positive clinical response. Requests without sufficient continuation-response evidence may not meet authorization requirements.

    • Submit chart notes demonstrating ongoing benefit from therapy.
    • For Piqray PROS and Vijoice, include the required measurable target-lesion volume reduction from baseline.
    Note

    Aliqopa Discontinued

    Aliqopa coverage criteria were removed from this policy because the medication was discontinued.

    • Do not rely on the former Aliqopa criteria for a current request under this policy.
    • The HCPCS code J9057 was also removed from the policy.
    The documented variant must be in either PIK3CD or PIK3R1.
    PIK3CA-related overgrowth spectrum (PROS)
    ConditionPIK3CA-related overgrowth spectrum (PROS).
    Imaging requirementThe individual must have at least one target lesion identified on imaging.
    Piqray diagnostic requirementPiqray criteria require a documented PIK3CA gene mutation.
    APDS
    Disease typeAPDS is a primary immunodeficiency.
    Molecular causeIt is caused by activating mutations in the PI3K-delta pathway, including documented variants in PIK3CD or PIK3R1.
    Joenja relevanceJoenja is indicated for adults and pediatric individuals 12 years of age and older with APDS.
    PROS
    Disorder groupPROS is a heterogeneous group of disorders.
    Associated featuresThe disorders are associated with vascular malformations and segmental overgrowth.
    Clinical coursePROS is characterized by early-onset, progressive symptoms and may involve high morbidity and mortality.
    Piqray (alpelisib) for breast cancer
    DrugPiqray (alpelisib) for breast cancer.
    Dose frequencyOnce daily.
    Maximum dose300 mg once daily.
    Piqray (alpelisib) for PROS
    DrugPiqray (alpelisib) for PIK3CA-related overgrowth spectrum (PROS).
    Dose frequencyOnce daily.
    Maximum dose250 mg once daily.
    Truqap (capivasertib)
    DrugTruqap (capivasertib).
    Dose400 mg twice daily.
    ScheduleTake for 4 days, followed by 3 days off.
    Vijoice (alpelisib)
    Ages 2–5 years50 mg once daily.
    Ages 6–17 years125 mg once daily.
    Age 18 years and older250 mg once daily.
    Zydelig (idelalisib)
    DrugZydelig (idelalisib).
    Total daily dose300 mg per day.
    AdministrationTaken as 150 mg twice daily.
    Piqray (alpelisib)
    DrugPiqray (alpelisib).
    Updated limitThe breast cancer dose is limited to 300 mg once daily.
    Update statusThe 2026 update added the 300 mg once-daily dose limitation to the Piqray breast cancer criteria.